Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Sponsor
Ting YANG
Study ID
NCT07188077
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Study Details

This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.

Key Dates

First listed
Sep 23, 2025
Start date
Mar 1, 2025
Status verified
Nov 2025
Primary completion
Mar 1, 2026
Completion
Mar 1, 2027

Study Design

Enrollment
20 participants (estimated)

Arms

  • Arm: PCNSL
    Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
  • Arm: GDLBCL
    Diffuse large B-cell lymphoma of the gastrointestinal tract
  • Arm: DLBCL
    Non-Hodgkin's diffuse large B-cell lymphoma not involving the central nervous system or gastrointestinal tract
  • Arm: Health
    Healthy control

Primary Outcome Measure

Metabolomics [ Time Frame: Before the start of the first treatment cycle, at the end of each treatment cycle(each cycle is 28 days) ]

Central Contacts

Related Studies